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Introduction
According to data from the Ministry of Health, 
Labour and Welfare of Japan in 2011, cerebrovascular 
disorder or stroke, is－by a very narrow margin－
the fourth most common cause of death in Japan, 
after cancer, cardiac disease and pneumonia. 
Furthermore, they are the most common cause of 
patients requiring care. Thus, the improvement of 
the outcomes of treatment for stroke is an issue 
that demands attention at the national level. It is 
well-known that strokes can be broadly divided into 
ischemic and hemorrhagic cerebrovascular disorders; 
however, the proportion of cerebral infarctions, 
which account for approximately three quarters of 
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―A study based on 10 years of stroke registry data—
　We studied ten years of stroke data registered with the Yamagata Society on Treatment for 
Cerebral Stroke（YSTCS）. The subjects included 16,407 cases of acute-phase cerebral infarction 
that were registered with the YSTCS during the ten years between 2002 and 2011. The cases were 
divided into two groups: the early phase group（2002-2006）and the late phase group（2007-2011）.
　The clinical diagnoses included atherothrombotic cerebral infarction（AT）（n=7,196; 43.9%）, 
cardiogenic cerebral embolism（CE）（n=4,011; 24.4%）, and lacunar infarction（LI）（n=4,703; 28.7%）. 
The average age of the early phase group was 72.7±11.43 years, while that of the late phase group 
was 75.0±11.35 years; the difference was statistically significant. The proportion of CE cases increased 
in the late phase, while that of LI decreased. This phenomenon was more marked in cases involving 
patients of ≥80 years of age. In both the early and late phase groups, the AT and CE cases showed a 
significantly high proportion of poor outcomes. However, when age adjustment was implemented in 
the late phase group, the treatment outcomes improved across all clinical entities. A multiple logistic 
regression analysis revealed a significant association between old age, female sex, severe symptoms 
at onset, CE, a previous history of stroke, and a poor prognosis.
　It is clear that developments in medicine have not kept pace with the advancement in the age 
at onset. The improvement of the outcomes of treatment for cerebral infarction requires further 
developments in acute-phase therapies and the primary prevention of cardiogenic cerebral embolism, 
many cases of which are severe.
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all strokes, is far higher, both in Japan and other 
countries１）－３）. In other words, an increasing number 
of patients is considered to require improved 
treatment results, especially for cerebral infarction.
A further notable change occurring in recent years 
has been the change in the clinical categorization 
of the subtypes of cerebral infarction based on 
the NINDS（National Institute of Neurological 
Disorders and Stroke）Classif ication Edition 
III４）; specifically, the proportion of atherothrombotic 
cerebral infarction, cardiogenic stroke, and lacunar 
infarction. Conventionally, lacunar infarction has been 
the most common form of stroke in Japan; however, 
in recent years the proportion of lacunar stroke has 
fallen, and the incidence rates of atherothrombotic 
cerebral infarction and cardiogenic stroke have been 
increasing５），６）. 
There is a wide range of factors that impact the 
effects of treatment for cerebral infarction. It is 
necessary to clarify these factors in order to improve 
the treatment results. In Yamagata Prefecture, 
the Yamagata Society on Treatment for Cerebral 
Stroke（YSTCS）was founded in 1998 for the 
purpose of eradicating stroke. This research group 
includes not only neurosurgeons, neurologists and 
radiologists specializing in stroke treatment, but 
also nurses, therapists, emergency and public sector 
workers, and the participating facilities include 
major hospitals throughout the prefecture. This 
facilitates a comprehensive understanding of the 
features of acute-phase stroke in the prefecture. 
Many reports have used community-based registries 
and hospital-based registries to ascertain the 
incidence of stroke and to analyze risk factors and 
prognosis５）－７）. However, it is difficult to cover 
all medical facilities within a community using 
a community-based registry, and since it is not 
guaranteed that patients will receive a specialist 
diagnosis and treatment, there are problems with 
accuracy and comprehensiveness of such reports. 
At the same time, while the use of hospital-based 
registries provides a high level of accuracy and data 
that can be precisely analyzed, their scope－in terms 
of the facilities that they cover－is narrow and since 
they tend to include minor cases and do not reflect 
the state of strokes in a particular region, they 
are thought to lack comprehensiveness. The data 
registered in the YSTCS registry consists of acute-
phase patients who underwent neuroradiological 
examinations and who were diagnosed, treated, and 
evaluated by specialists. Furthermore, almost all 
of the facilities to which patients with acute-phase 
stroke are admitted participate in the registry. 
Thus, although the YSTCS registry is hospital-based 
registry, it is considered highly comprehensive and 
is thought to provide an accurate picture of the state 
of strokes within Yamagata Prefecture, where 1% of 
Japan’s population resides８）.
We studied the data on strokes that were 
registered with the YSTCS over the past ten years 
in order to investigate the factors associated with a 
worse prognosis in cerebral infarction and to clarify 
the factors that are in its treatment, with the aim of 
improving the outcomes of cerebral infarction in the 
future.
Patients and Methods
［Patients］The study population included 16,407 
patients（male, n=9,567; female, n=6840; average 
age, 74.0±11.44 years）with acute-phase cerebral 
infarction whose cases were registered with the 
YSTCS during the ten years between 1st January 
2002 and 31st December 2011. The clinical diagnoses 
included atherothrombotic cerebral infarction（AT）
（n=7,196; 43.9%）, cardiogenic cerebral embolism 
（CE）（n=4,011; 24.4%）, and lacunar infarction（LI）
（n=4,703; 28.7%）; 497（3.0%）cases were classed as 
“other”（OT）. The characteristics of the patients 
are shown in Table 1.
The factors that were analyzed included age, 
gender, severity at onset, final outcome（time to 
discharge or ADL at one month after onset）, risk 
factors（hypertension, atrial fibrillation, diabetes, 
hyperlipidemia and a history of smoking）, and a 
history of stroke.
［Diagnosis of clinical categories］Stroke specialists 
in each facility used computed tomography（CT）
and magnetic resonance imaging（MRI）, as well as 
medical history, blood tests and a detailed cardiac 
examination by a cardiovascular specialist, in order 
to provide an integrated decision based on the 
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definitions in NINDS Classification Edition III４）.
The evaluation of the severity at onset and the 
final outcome（time to discharge or ADL at one 
month after onset）was made using the following 
five categories: E（excellent: almost fully recovered, 
with no impediment to working or household tasks）; 
G（good: some symptoms remain, but working or 
household tasks, and independent daily living, are 
possible）, F（fair: clear symptoms remain, and some 
assistance is required for activities of daily living）, P
（poor: assistance is required for most activities of 
daily living）, and D（dead）. E and G were defined 
as good prognoses, while F, P and D were defined as 
poor prognoses. The risk factors and the patient’s 
history of stroke were confirmed by interviewing 
either the patient or his/her family when they 
attended the hospital.
［Categories evaluated］（1）The proportions of 
cases in each clinical category,（2）the treatment 
results according to the final outcome, and（3）
factors associated with a poor prognosis（final 
outcomes F, P and D）. Furthermore, the data from 
the ten-year study period were divided into two 
groups, the early phase group（2002-2006）and the 
late phase group（2007-2011）, and analyzed in order 
to clarify recent trends. Additionally, in order to 
consider the contribution of age, the age distribution 
of the late phase group was adjusted in line with 
that of the early phase group, and then the same 
categories were studied.
［Statistical analysis］The clinical entities and 
treatment outcomes in both the early and late phases 
were compared using a chi-squared test and a 
residual test, while age was compared using a t-test. 
The factors associated with good or poor prognoses 
were considered using a good or poor prognosis 
as objective variables, and performing univariate 
and multivariate logistic regression analyses. Atrial 
fibrillation, which is believed to be strongly correlated 
with CE, was omitted as an explanatory variable in 
the multivariate logistic regression analysis. In all 
cases, p values of <0.05 were considered to indicate 
statistical significance.
This research project was implemented with the 
approval of the ethical committees of Yamagata 
University and the cooperating facilities.
Results
［Age distribution］
The average age of the late phase group（75.0±
2002-2011 2002-2006 2007-2011
characteristics
Patient (no.) 16407 7565 8842
≥ 80 yr 5626 2158 3468
<80yr 10781 5407 5374
Age, yr 74.0±11.44 72.7±11.43 75.0±11.35*
≥ 80 yr(%) 34.3 28.5 39.2
<80yr (%) 65.7 71.5 60.8
Male sex(%) 58.3 58.1 58.5
≥ 80 yr(%) 41.5 40 42.4
<80yr (%) 67.1 65.3 68.9
subtype of infarction 
(%)
Atherothrombotic 43.9 44.4 43.4
≥ 80 yr 44 45 43.5
<80yr 43.8 44.1 43.4
Cardioembolic 24.4 22.6 26
≥ 80 yr 30.6 28.5 31.9
<80yr 21.2 20.3 22.2
Lacunar infarction 28.7 30.5 27.1
≥ 80 yr 23.3 25 22.3
<80yr 31.4 32.7 30.3
Other 3 2.5 3.4
≥ 80 yr 2 1.5 2.4
<80yr 3.6 2.9 4.1
Medical history
Hypertension (%)
yes 66.5 64.3 68.3
≥ 80 yr 66.6 64.6 67.9
<80yr 66.4 64.2 68.6
Atrial fibrillation(%)
yes 22.3 20.5 23.9
≥ 80 yr 29.6 27.8 30.7
<80yr 18.5 17.6 19.5
Diabetes mellitus (%)
yes 33.6 32.5 34.6
≥ 80 yr 28.8 28.4 29.1
<80yr 36.1 34.1 38.1
Hyperlipidemia (%)
yes 17.9 16.3 19.3
≥ 80 yr 14.1 11.4 15.9
<80yr 19.9 18.3 21.5
Smoking(%)
yes 25.5 24.2 26.5
≥ 80 yr 13.8 12.2 14.8
<80yr 31.6 29 34.1
Previous stroke(%)
yes 24.4 22.2 26.3
≥ 80 yr 27.8 25 29.6
<80yr 22.6 21.1 24.2
*P<0.01
Table１．The patient characteristics
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11.35 years）was significantly higher than that of 
the early phase group at 72.7±11.43（t-test, p<0.01）. 
Figure 1 shows the distribution of cases in each 
age group, in the early and late phases. The total 
number of cases in the late phase group was greater 
than that of the early phase group, which depended 
mainly on the difference in the number of patients 
aged 75 years and older. Furthermore, in terms of 
the clinical categories, the total number of cases in 
the late phase group was greater than that of the 
early phase group in all categories, especially in 
CE cases, which depended mainly on the difference 
in the number of patients aged 75 years and older
（Figure 2）.
Clinical categories
A comparison of the proportions of each type of 
cases in the early and late phase groups showed 
that in the early phase group, there were 3,357 
cases of AT（44.4%）, 1,711 cases of CE（22.6%）, 
2,305 cases of LI（30.5%）and 192 OT cases（2.5%）, 
while in the late phase group there were 3,839 cases 
of AT（43.4%）, 2,300 cases of CE（26%）, 2,398 
cases of LI（27.1%）, and 305 OT cases（3.4%）. The 
proportion of CE cases increased during the late 
phase, while the proportion of LI cases decreased. 
This phenomenon was more marked in the cases 
involving patients of ≥80 years of age（Table 1）. 
When adjusted for age, the incidence rates in the late 
phase group were as follows: AT, 43.4%; CE, 24.7%; 
LI, 28.1%; and OT, 3.8%; the proportion of CE cases 
was slightly reduced, which brought the distribution 
closer to that of the early phase group.
Treatment outcomes
The prognoses of all cases from 2002 to 2011 were 
as follows:（E: n=4,494, 27.4%; G: n=4,956, 30.2%）; F 
（n=3,280, 20%）; P（n=2,726, 16.6%）; and D（n=951, 
5.8%）. The classifications during the early phase
（2002-2006）were as follows: E（n=2,153, 28.5%）; G,
（n=2,325, 30.7%）; F（n=1,621, 21.4%）; P（n=1,034, 
13.7%）; and D（n=432, 5.7%）. The classifications 
during the late phase（2007-2011）were as follows: E
（n=2,341, 26.5%）; G（n=2,631, 29.8%）; F（n=1,659; 
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Figure１．The age distribution in the early phase （2002-2006） and late phase （2007-2011） groups.
The number of patients in the late phase group was increased in comparison to the early phase group, 
which depended mainly on the difference in the number of patients aged 75 years and older.
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18.8%）; P（n=1,692; 19. 1%）; and D（n=519; 5.9%）. 
Thus, the proportions of E and G cases in the late 
phase were lower than those in the early phase; the 
proportion of P cases in the late phase was higher 
than that in the early phase（chi-squared test and 
residual test, p<0.01）. When the late phase was 
adjusted for age, the proportions were as follows: E, 
29.4%; G, 30.7%; F, 17.9%; P, 16.8% and D, 5.1%. The 
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Figure２．The age distribution in each clinical category of the early phase （2002-2006） and late phase （2007-2011） 
groups.
The number of patients in the late phase group was increased in comparison to the early phase group, which depended 
mainly on the difference in the number of patients aged 75 years and older, especially patients with cardiogenic 
cerebral embolism （CE）.
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Figure３．The rates of each outcome in the early phase （2002-2006） and late phase （2007-2011） groups.
The graph shows that in the late phase group, the proportions of E and G cases were lower, while the proportion of P 
cases was higher in comparison to the early phase group （chi-squared test and residual test, p<0.01）.
When the late phase was adjusted for age to match the early phase†, the proportion of combined E and G cases 
increased in comparison to the early phase group.
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combined proportion of E and G cases was higher 
in comparison to the early phase（Figure 3）. At the 
same time the proportion of E, G and F cases among 
patients of ≥80 years of age in the late phase group 
was low, and the proportion of P cases was high in 
comparison to the early phase group（chi-squared 
test and residual test, p<0.01）（Figure 4）.
［The treatment outcomes according to the clinical 
categories］
In both treatment groups, among the clinical 
categories ,  the AT and CE cases showed a 
significantly high proportion of poor outcomes, while 
the LI cases showed a significantly high proportion 
of good outcomes（chi-squared test, p<0.05）. The 
late phase group tended to show lower proportions 
of good outcomes（E and G）, and higher proportions 
of P and D（considered to be poor outcomes）in 
comparison to the early phase group. The average 
age was significantly higher across all clinical entities 
in the late phase group（t-test, p<0.01）. Furthermore, 
when the late phase group was adjusted for age, 
the treatment outcomes improved across all clinical 
entities, with a higher proportion of good outcomes（E 
and G）in comparison to the early phase cases（Figure 
5）.
［The factors associated with poor outcomes］
Table 2 shows the results of the univariate 
analysis of the factors associated with poor outcomes, 
which investigated the correlations between the 
risk factors, stroke history, age, gender, severity at 
onset and CE or non-CE, and a poor prognosis. Old 
age, female sex, severe symptoms at onset, atrial 
fibrillation, a history of smoking, CE and a previous 
history of stroke were significantly correlated with 
a poor prognosis. The results of a multiple logistic 
regression analysis that included these factors using 
explanatory variables other than the presence of 
atrial fibrillation－which is strongly correlated with 
CE－are shown in Table 3. Significant associations 
were observed between old age, female sex, severe 
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2002-2011
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*
E G F P D
E G F P D
*
*
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Figure４．The rates of each outcome in the early phase （2002-2006） and late phase （2007-2011） groups.
Striped columns show each outcome in over 80 years of age*.
The proportions of E, G and F cases among patients of ≥80 years of age in the late phase group were low, and the 
proportion of P cases was high in comparison to the early phase group （chi-squared and residual test, p<0.01）.
2002-2011 (n=16407)
Odds ratio 95% CI p value
Age 1.067 (1.064-1.071) <0.01
Sex (female) 1.795 (1.686-1.912) <0.01
Severity of stroke 11.043 (10.291-11.849) <0.01
Hypertension 0.919 (0.860-0.981) 0.0111
Atrial fibrillation 2.455 (2.227-2.646) <0.01
Diabetes mellitus 0.965 (0.903-1.030) 0.283
Hyperlipidemia 0.643 (0.592-0.699) <0.01
Smoking 0.599 (0.557-0.645) <0.01
Previous stroke 1.808 (1.683-1.943) <0.01
CE or non-CE 2.763 (2.567-2.973) <0.01
Table２．The factors significantly associated with a poor 
prognosis （univariate logistic regression analysis）
2002-2011 (n=16407)
Odds ratio 95% CI p value
Age 1.067 (1.064-1.071) <0.01
Sex (female) 1.795 (1.686-1.912) <0.01
Severity of stroke 11.043 (10.291-11.849) <0.01
Hypertension 0.919 (0.860-0.981) 0.0111
Atrial fibrillation 2.455 (2.227-2.646) <0.01
Diabetes mellitus 0.965 (0.903-1.030) 0.283
Hyperlipidemia 0.643 (0.592-0.699) <0.01
Smoking 0.599 (0.557-0.645) <0.01
Previous stroke 1.808 (1.683-1.943) <0.01
CE or non-CE 2.763 (2.567-2.973) <0.01
2002-2011 (n=16407)
Odds ratio 95% CI p value
Age 1.067 (1.064-1.071) <0.01
Sex (female) .795 ( .686- .912) .
verity of stroke 11.043 (10.291- 1.849) .
Hypertension 0.919 ( .860-0.9 1) 0. 111
Atrial fibrillation 2.455 (2.227-2.646) < .01
Diabetes mellitus 0.96 (0.903-1.030) 0.283
Hyperlipidemia .643 ( .592-0.699) <0.01
Smoking .599 ( . 57- . 45) .
Previous stroke 1.808 (1.683-1.9 3) .
CE or non-CE 2.763 (2.567-2. 7 ) .
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symptoms at onset, CE, a previous history of stroke, 
and a poor prognosis.
Discussion
Almost all of the facilities to which acute-phase 
stroke are admitted in Yamagata were registered 
their data with the YSTCS. Thus, despite the fact 
that this is a hospital-based registry, the results are 
highly comprehensive. However, there is a limitation 
in that some patients with minor or asymptomatic 
stroke might have been excluded. A study９）from 
Akita prefecture（2004 population: 1,159,000）, which 
is located next to Yamagata（2004 population: 
1,223,000）, reported that 18,018 cases of cerebral 
infarction（CI）occurred over a 10-year period（1995-
2004）. Thus, the comprehensiveness of the results is 
almost comparable to the results of the Akita study. 
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Figure５．The rates of each outcome in the early phase （2002-2006） and late phase （2007-2011） groups according to 
the clinical category.
In the late phase group, the proportions of P and D increased in all clinical categories in comparison to the raw data of 
the early phase group （chi-squared and residual test, p<0.01）. However, after adjusting the late phase group for age† 
（to match the early phase group）, the proportions of E and G in all clinical categories were higher in comparison to the 
early phase group.
AT: atherothrombotic infarction, CE: cardiogenic cerebral embolism, LI: lacunar infarction
2002-2011 (n=16407) 2002-2006 (n=7565) 2007-2011 (n=8842)
Odds ratio 95% CI p value Odds ratio 95% CI p value Odds ratio 95% CI p value
age 1.044 (1.04-1.049) <0.01 1.04 (1.034-1.047) <0.01 1.049 (1.043-1.055) <0.01
sex (female) 1.322 (1.204-1.453) <0.01 1.234 (1.071-1.421) <0.01 1.402 (1.235-1.591) <0.01
severity of stroke 9.766 (9.075-10.509) <0.01 12.123 (10.804-13.602) <0.01 8.289 (7.534-9.120) <0.01
hypertension 0.908 (0.829-0.995) 0.039 0.909 (0.793-1.043) 0.175 0.991 (0.805-1.031) 0.138
hyperlipidemia 0.819 (0.730-0.918) <0.01 0.882 (0.737-1.056) 0.171 0.781 (0.673-0.907) <0.01
smoking 0.983 (0.882-1.096) 0.787 0.883 (0.749-1.042) 0.135 1.079 (0.934-1.248) 0.302
previous stroke 1.696 (1.538-1.871) <0.01 1.787 (1.534-2.081) <0.01 1.642 (1.444-1.866) <0.01
CE or non-CE 1.36 (1.190-1.553) <0.01 1.459 (1.188-1.793) <0.01 1.288 (1.081-1.535) <0.01
Table３．The factors significantly associated with a poor prognosis （multiple logistic regression analysis）
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The present study showed that in the late phase 
group, the proportion of cases that were categorized 
as lacunar infarction was smaller, and the number of 
cardiogenic cerebral embolism cases was increased 
in comparison to the early phase group. This reflects 
findings from a study in Hisayama town５）, and might 
indicate a reduction in lacunar infarction due to 
recent improvements in blood pressure control. At 
the same time, the Westernization of both diet and 
lifestyle has led to increased rates of obesity, diabetes 
and hyperlipidemia, and this is considered to be a 
factor in the increasing numbers of both cardiogenic 
cerebral embolism and atherothrombotic cerebral 
infarction cases10）. The proportions of patients with 
diabetes and hyperlipidemia in the late phase were 
higher than those in the earlier phase of the present 
study（Table 1）, and the issue of preventing the 
onset of future cerebral infarction needs to be 
considered in light of these findings.
In terms of the treatment outcomes, the late 
phase included a higher proportion of cases with a 
poor prognosis in comparison to the earlier phase. A 
recent report on the outcomes of cerebral infarction 
treatment provided the largest stroke databank 
from a hospital-based registry in Japan. The results 
from that study also showed that in 2005 to 2007, 
the proportions of cases with good outcomes were 
decreased across all categories（atherothrombotic 
cerebral infarction, cardiogenic cerebral embolism 
and lacunar infarction）in comparison to the data 
registered from 2000 to 200411），12）. In other words, the 
results were similar to those of the present study, in 
which no improvement in the treatment outcomes 
was seen over the latter part of the study. However, 
after adjustment for age, the treatment outcomes in 
the late phase were better than those in the early 
phase, and it is considered that age may have had a 
significant impact on this result. In the present study, 
the average age at onset in the early phase was 72.7
±11.43 years, while that in the late phase was 75.0
±11.35; the difference was statistically significant
（p<0.01）. According to the National Census data 
from 2000, 3.82% of the national population and 5.11% 
of the population of Yamagata Prefecture was ≥80 
years of age, while in 2010 these proportions had 
almost doubled to 6.35% nationwide and 9.38% in 
Yamagata Prefecture.
One more issue that should be noted is the fact 
that the proportion of lacunar infarction（which 
has a good prognosis）in the late phase group fell 
in comparison to the early phase group, while the 
proportion of cardiogenic cerebral embolism（which 
has a poor prognosis）, rose. Despite the fact that 
the proportion of cardiogenic cerebral embolism fell 
when adjusted for age, patients become more likely 
to develop non-valvular atrial fibrillation, which is 
the greatest risk factor for cardiogenic cerebral 
embolism, with advancing age13），14）. It is likely that 
this contributed to the increased proportion of 
cardiogenic cerebral embolism cases. In other words, 
diagnosis and treatment of cerebral infarction have 
definitely advanced because of the results in the late 
phase group after age adjustment has improvement 
tendency, but the current situation is that medical 
advancements can hardly keep up with the higher 
age at onset of stroke.
The multiple logistic regression analysis revealed 
that age, female sex, severe symptoms at onset, CE, 
and a previous history of stroke were significantly 
associated with a poor prognosis in cases of cerebral 
infarction. Previous studies of female patients did 
not clearly explain the biological reasons associated 
with the sex differences, and many reports seem 
to suggest that social factors（i.e., living alone or 
admittance to a residential facility）may contribute 
to this result15），16）.
The results of the present study have implications 
when considering how to improve treatment 
outcomes for cerebral infarction in the future. 
Firstly, severe symptoms at onset are associated 
with a poor prognosis; thus the treatment outcomes 
of acute-phase cerebral infarction require further 
improvement. rt-PA infusion treatment is still 
only used in the treatment of 5.2% of cerebral 
infarction patients17）, even in studies reporting its 
use in the treatment of a high proportion of cases, 
and a good prognosis was reported to have been 
achieved in 33.1–39.0% of rt-PA-treated cases18），19）. 
A good prognosis was reported in 42% of cases in 
which mechanical thrombus collection therapy was 
performed in the hyper acute-phase20）, and further 
improvements are anticipated. These methods 
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have only just been approved and the number of 
institutions implementing them is still relatively 
small; thus, there is an issue with regard to ensuring 
that the number of cases to which these treatment 
modalities are applied increases in the future. For 
this reason, further developments in acute-phase 
therapies are required. In particular, the primary 
prevention of cardiogenic cerebral embolism, which 
has a particularly poor prognosis, is believed to be an 
extremely important issue.
When considering the primary prevention 
of cardiogenic cerebral embol ism, the main 
target becomes patients with non-valvular atrial 
fibrillation. To date, treatment has consisted of 
the administration of the anticoagulant warfarin; 
however, 2–6.6% of patients who receive warfarin 
suffer from the complication of intracranial 
hemorrhage21）－23）. As such, warfarin is not been 
widely used in primary prevention. More recently 
direct oral anticoagulants that are associated with 
a lower incidence of intracranial hemorrhage in 
comparison to warfarin24），25）have been approved, 
and physicians no longer need to be hesitant in 
administering these drugs as a means of primary 
prevention. The application of anticoagulant therapy 
in the treatment of non-valvular atrial fibrillation, the 
major risk factor in cardiogenic cerebral embolism, 
has previously been determined based on the 
patient’s CHADS226）score（one point each for C
［congestive heart failure］, H［hypertension］, A
［age≥75 years］and D［diabetes mellitus］, and 
two points for S［stroke］）. Recently, however, the 
more accurate CHA2DS2-VASc27）score（in which 
one point is awarded for V［vascular disease］A
［age 65-74 years］and S［female sex］）has been 
recommended for identifying cases in which the 
additional use of anticoagulants is considered to be 
associated with less risk. The stricter application of 
primary prevention methods for cardiogenic cerebral 
embolism will be necessary in the future.
Conclusions
The analysis of the stroke data registered in 
YSTCS revealed that in the late phase（2007-2011）
there was a reduction in the incidence of lacunar 
infarction and an increase in the incidence of 
cardiogenic cerebral embolism in comparison to the 
early phase（2002-2006）. However, after adjustment 
for age, the outcomes tended to improve in the late 
phase. In other words, while definite progress has 
been made in the diagnosis and treatment of cerebral 
infarction, it is clear that developments in medicine 
have not kept pace with the advance in age at the 
onset of stroke. Furthermore, the present study 
clarified that female sex, old age, severe symptoms at 
onset, cardiogenic cerebral embolism and a previous 
history of stroke were independently associated with 
a poor prognosis in patients with cerebral infarction.
Improving the outcomes of treatment for cerebral 
infarction will require further developments in acute-
phase therapies and the primary prevention of 
cardiogenic cerebral embolism, many cases of which 
were severe. In other words, it will be necessary 
to thoroughly and strictly administer anticoagulant 
treatment to patients with non-valvular atrial 
fibrillation, which is the main cause of cardiogenic 
cerebral embolism.
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